Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 440

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 440
---
, at a purchase price of $3.10 per common share, for aggregate gross proceeds of up to $1million. The offering was structured in two tranches, with the first tranche of $500,000 closing in January 2025 following shareholder approval. The proceeds from the offering were intended to support our general corporate purposes and our proposed Merger with Kadimastem. The second tranche of $500,000 may occur, at the election of the investor, within 15 days following the Company meeting certain conditions, including the receipt of shareholder approval and the NLS Common Shares trading for at least ten consecutive trading days above the purchase price of $3.10, which corresponds to an approximate 15% premium. As of August28, 2025, the condition for the second tranche has not yet occurred. The Company uses and intends to further use the net proceeds from the offering for working capital and general corporate purposes. On March27, 2025, we entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122 NLS Preferred Shares with a conversion price of $1.65 per share, as well as warrants to purchase 787,880 NLS Common Shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $2million. The March 2025 Offering initially closed on March28, 2025. Pursuant to 236 the terms of the March 2025 SPA, the investors may purchase up to $1million of additional NLS Preferred Shares on identical terms as the initial closing, subject to the Company obtaining shareholder approval. On June26, 2025, we executed an amendment, or the Amendment, to the March 2025 SPA. Pursuant to the terms of the Amendment, the investors agreed to purchase PPCs in lieu of NLS Preferred Shares with the same rights and privileges as the NLS Preferred Shares. Pursuant to the terms of the Amendment, the Company agreed to issue 568,278 PPCs and 37,783 NLS Preferred Shares, as well as warrants to purchase 393,939 NLS Common Shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $1million. The second closing occurred on June27,